NOVOCURE LIMITED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.74 USD | -0.83% |
|
+1.18% | -10.54% |
| Dec. 02 | HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating | MT |
| Dec. 02 | NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint | MT |
EPS & Dividend: NovoCure Limited
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.07 | 0.2 | -0.56 | -0.88 | -1.95 | -1.296 | -1.598 | -1.608 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Reference price 2 | 84.27 | 173.04 | 75.08 | 73.35 | 14.93 | 26.96 | 26.96 | 26.96 |
| Nbr of stocks (in thousands) | 98,969 | 101,797 | 103,819 | 104,950 | 106,861 | 108,201 | 108,201 | - |
| Announcement Date | 2/27/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Upcoming events: NovoCure Limited
More events
| Yield | Yield | P/E ratio | Price to Book | EV / Sales | ||
|---|---|---|---|---|---|---|
| - | - | - | - | - | ||
| -.--% | -.--% | 633.91x | 9.196 | 8.4x | ||
| - | - | 100.68x | - | 3.56x | ||
| +2.26% | +2.58% | 26.7x | 1.729 | 1.88x | ||
| +0.50% | +0.66% | 50.9x | 15.15 | - | ||
| +1.69% | +1.81% | 16.8x | 2.652 | - | ||
| -.--% | -.--% | -67.18x | 10.38 | 7.67x | ||
| +0.94% | +1.07% | 35.57x | 4.265 | 5.54x | ||
| +0.49% | +0.89% | 44.73x | 2.433 | - | ||
| Average | +0.84% | +1.00% | 105.26x | 6.54 | 5.41x | |
| Weighted average by Cap. | +0.75% | +0.86% | 175.06x | 7.37 | 5.62x |
